Shares of Lupin Ltd fell 2% on sixth October after touching a day’s excessive of Rs 1,972.90. This occurred as the corporate introduced that the US drug regulator has categorised its inspection of the Pithampur Unit 2 manufacturing facility as ‘official motion indicated’ (OAI).
The USFDA inspected Lupin’s Pithampur Unit 2 plant between eighth and seventeenth July, 2025. It later issued a Kind 483 with 4 observations.
In an trade submitting on Saturday, Lupin acknowledged that it’s working intently with the US USFDA to resolve the problems. It stays dedicated to adhering to present good manufacturing practices (CGMP) throughout all its amenities.
Individually, on third October, Lupin introduced the launch of Liraglutide injection within the US. The drug, accessible in an 18 mg/3 mL prefilled pen, is used with weight loss program and train to handle blood sugar in adults and kids over 10 years with sort 2 diabetes.
The injection is a bioequivalent model of Victoza, manufactured by Novo Nordisk. It generates annual US gross sales of roughly $350 million.
At 10:50 AM, the shares of Lupin Ltd have been buying and selling 1.78% decrease at Rs 1,938.50 on NSE.
Prepared to speculate like a professional? Unicorn Alerts app equips you with 100+ Free instruments and data it’s essential succeed. Obtain the Unicorn Alerts app and acquire entry to every day inventory lists and insightful market evaluation and way more!
and meanwhile, a https://vechain-wallet.com wallet is better to apply both with interesting, and with cold wallets, to take advantage of the convenience of the first or the security of the second.